Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca

Amgen Inc. (NASDAQ: AMGN ) and AstraZeneca PLC (NYSE: AZN ) received a positive boost after their combination of Amgen's Imdelltra and AstraZeneca's Imfinzi significantly improved overall survival in a late-stage trial involving patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial therapy.

Beyond overall survival, the combination also improved progression-free survival and response rates, with no new safety concerns identified. For Amgen, the result is particularly relevant because Imdelltra generated $513 million in sales last year and could now have a broader role in the treatment of small-cell lung cancer.

The trial strengthens the commercial outlook for Imdelltra and gives Amgen Inc. (NASDAQ:AMGN) another opportunity to expand one of its newer oncology assets beyond its existing use. Imdelltra already has full U.S. approval for extensive-stage small-cell lung cancer, and demonstrating an overall-survival benefit when combined with Imfinzi could make the drug more important earlier in the treatment journey. Since cancer therapies already account for roughly 23% of Amgen's sales, a successful expansion of Imdelltra could further diversify the company's revenue base and reduce reliance on its older products. The fact that the combination improved not only overall survival but also progression-free survival and response rates makes the result more commercially meaningful than a single positive endpoint. Amgen's broader business is also entering this result from a position of strength, with second-quarter 2026 revenue up 10% and sales of key growth products increasing substantially.

The result provides another positive data point for AstraZeneca PLC (NYSE:AZN)'s large oncology franchise and potentially extends the commercial opportunity for Imfinzi, one of its established cancer drugs. Because Imfinzi is already approved across several cancer indications, demonstrating that it can work effectively in combination with Imdelltra could reinforce its position in small-cell lung cancer and support additional revenue from combination-based treatment. More importantly, the positive survival result comes at a useful time for AstraZeneca, whose investor confidence has recently been pressured by clinical setbacks, including the discontinuation of its volrustomig lung-cancer trial. The success therefore gives investors evidence that AstraZeneca's oncology pipeline still has meaningful depth, while the company continues targeting $80 billion in annual revenue by 2030.